Meet the BD&L Team 2019 Meet the BD&L Team 2019 Hear from our team and find out more about our approach to partnering.
Moving towards a rabies-free Southeast Asia Moving towards a rabies-free Southeast Asia Boehringer Ingelheim, in collaboration with Eco-Business, has published a comprehensive whitepaper to stop rabies.
BI X colleague about working with purpose BI X colleague about working with purpose Ding works on an app that gives patients remote access to stroke rehabilitation via their mobile phones and tablets
Boehringer Ingelheim Human Pharma Clinical Pipeline Boehringer Ingelheim Human Pharma Clinical Pipeline Boehringer Ingelheim Human Pharma Clinical Pipeline
Boehringer Ingelheim Human Pharma Clinical Pipeline dynamic Boehringer Ingelheim Human Pharma Clinical Pipeline dynamic Boehringer Ingelheim Human Pharma Clinical Pipeline dynamic
Boehringer Ingelheim Business Services Philippines Inc. | Careers Boehringer Ingelheim Business Services Philippines Inc. | Careers Boehringer Ingelheim Business Services Philippines Inc. | Careers
Daniel Kiesenhofer Daniel Kiesenhofer Diverse, caring, collaborative - Daniel Kiesenhofer on Boehringer Ingelheim
Diversity Diversity At Boeheringer Ingelheim, we believe in a diverse working culture. Find out what our people like most about working with us.
Ann-Kathrin Koller Ann-Kathrin Koller Diverse, caring, collaborative - Ann-Kathrin Koller on Boehringer Ingelheim
First Translational Medicine Award awarded First Translational Medicine Award awarded The Award recognizes the research that has the highest translational potential
Animal Welfare through environmental sustainability Animal Welfare through environmental sustainability Producing honey and contributing to environmental sustainability during your work hours.
cystic fibrosis phase II trial cystic fibrosis phase II trial The first patient has been enrolled in a phase II trial to evaluate an innovative treatment for cystic fibrosis, inhaled via the Respimat® inhaler
Partnership canine oncology Partnership canine oncology The collaboration will focus on identifying new molecules to target cancers in dogs. Small molecules could provide superior disease control.
Lameness horses collaboration Sleip app artificial intelligence Lameness horses collaboration Sleip app artificial intelligence The Sleip app uses artificial intelligence (AI) to provide objective analysis of a horse’s movement with just a smartphone.
FIBRONEER™ Phase III program initiated FIBRONEER™ Phase III program initiated FIBRONEER™ Phase III program initiated globally to evaluate BI 1015550, a novel investigational phosphodiesterase 4B (PDE4B) inhibitor
Inauguration of new global center for veterinary vaccine R&D Inauguration of new global center for veterinary vaccine R&D Inauguration of a new global hi-tech centre for biological research and development in Lyon.
Positive-CHMP-opinion-for-dabigatran-in-children Positive-CHMP-opinion-for-dabigatran-in-children Positive CHMP opinion received for use of dabigatran for the treatment and prevention of venous thromboembolic events in children
New Therapeutic Antibody Discovery Collaboration New Therapeutic Antibody Discovery Collaboration Proprietary antibody libraries to help discover therapeutic antibodies against multiple targets
DCRI-collaboration-empact-mi DCRI-collaboration-empact-mi Collaboration with Duke Clinical Research Institute on EMPACT-MI trial, which will assess outcomes in people who have had a myocardial infarction
Phase II clinical trial weight loss results Phase II clinical trial weight loss results Data shows nearly 19% weight loss in people with overweight or obesity in Phase II trial with survodutide (BI 456906)
We are Global Top Employer 2024 We are Global Top Employer 2024 Global Top Employer certification reflects our impactful people development with high scores in development and steering practices as well as benefits on employee wellbeing.